Prof. Raffaele Calogero Seminar, 16th April 2009, 2.30 p.m., Conference Room T1 Building, Area Science Park, Basovizza, Trieste

[clara.finzi at cbm.fvg.it]

Dear All,

You are kindly invited to the seminar " VACCINE FOR CANCER PREVENTION:
MINING BREAST CANCER TRANSCRIPTOME FOR THE IDENTIFICATION OF NEW
ONCOANTIGENS ", to be held on April 16th, 2009, at 2.30 pm, Conference
Room, T1 Building, Area Science Park, Basovizza, Trieste by Prof. Raffaele
Calogero, Bioinformatics and Genomics Unit - Dip. Scienze Cliniche e
Biologiche, Az. Ospedaliera S. Luigi Orbassano, Torino.


We would be most pleased if you could let us know your availability to
attend.

Thank you,

Clara Finzi

 

 

 

 

 


------------------------
Speaker:
------------------------
Prof. Raffaele Calogero

Bioinformatics and Genomics Unit - Dip. Scienze Cliniche e Biologiche
Az. Ospedaliera S. Luigi
Orbassano - Torino

 <http://publicationslist.org/raffaele.calogero>
http://publicationslist.org/raffaele.calogero

------------------------
Title:
------------------------
VACCINE FOR CANCER PREVENTION: MINING BREAST CANCER TRANSCRIPTOME FOR THE
IDENTIFICATION OF NEW ONCOANTIGENS.

------------------------
Abstract:
------------------------
Neoplastic transformation is a multistage process and distinct gene
products of specific cell regulatory pathways are involved at each stage.
Identification of genes overexpressed at a specific stage provides an
unprecedented opportunity to address the immune system against antigens
with a driving role in tumor progression (oncoantigens). The ERBB2
oncogene is a prototype of deregulated oncogenic protein kinase membrane
receptors. Mice transgenic for rat ERBB2 (BALB-neuT mice) were used to
identify an additional set of oncoantigens expressed at defined stages by
most breast carcinomas to be used as alternatives to ERBB2-driven
vaccination. To address this question, we integrated the transcription
data generated by comparing preneoplastic lesions and neoplasia in
BALB-neuT mice with a meta-analysis on transcription profiles generated
from normal and breast tumor human specimens. Forty-six putative
oncoantigens identified and prioritized according to their expression on
the cell membrane or in the extra cellular space, cytoplasm and nucleus
were chosen for preclinical investigation as vaccination targets. The
protective immune response elicited by a subset of them was evaluated in
BALB-neuT mice in their distinct autochthonous mammary cancer stages.
Furthermore, data on the role played by miRNAs in cancer progression by
mean of characterization of their expression profile during carcinogenesis
in BALB-neuT were also acquired.

------------------------
Selected Bibliography:
------------------------
Quaglino E, Rolla S, Iezzi M, Spadaro M, Musiani P, De Giovanni C, Lollini
PL, Lanzardo S, Forni G, Sanges R, Crispi S, De Luca P, Calogero R,
Cavallo F.
Concordant morphologic and gene expression data show that a vaccine halts
HER-2/neu preneoplastic lesions.
J Clin Invest. 2004 Mar ;113(5):709-17.

Astolfi A, Rolla S, Nanni P, Quaglino E, De Giovanni C, Iezzi M, Musiani
P, Forni G, Lollini P, Cavallo F, Calogero RA.
Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice:
a microarray scenario.
Cancer Immunol Immunother. 2005 Jun ;54(6):599-610.

Cavallo F, Astolfi A, Iezzi M, Cordero F, Lollini P, Forni G, Calogero R.
An integrated approach of immunogenomics and bioinformatics to identify
new Tumor Associated Antigens (TAA) for mammary cancer immunological
prevention.
BMC Bioinformatics. 2005 Dec 1;6 Suppl 4S7.

Cavallo F, Calogero RA, Forni G.
Are oncoantigens suitable targets for anti-tumour therapy?
Nat Rev Cancer. 2007 Sep ;7(9):707-13.

Calogero RA, Quaglino E, Saviozzi S, Forni G, Cavallo F.
Oncoantigens as anti-tumor vaccination targets: the chance of a lucky
strike?
Cancer Immunol Immunother. 2008 Nov ;57(11):1685-94.